[Federal Register Volume 59, Number 79 (Monday, April 25, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-9932]
[[Page Unknown]]
[Federal Register: April 25, 1994]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health; HHS.
ACTION: Notice.
-----------------------------------------------------------------------
The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for U.S. companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
Licensing Specialist at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, suite 325, Rockville,
Maryland 20852-3804 (telephone 301/496-7735; fax 301/402-0220). A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications. Issued patents may be obtained from
the Commissioner of Patents, U.S. Patent and Trademark Office,
Washington, DC 20231.
Attenuation of Ethyl Alcohol Intoxication With 2 Adrenoceptor
Antagonists
Linnoila, M., Lister, R., Durcan, M. (NIAAA)
Serial No. 07/512,835 (DIV of 07/294,119)
U.S. Patent No. 5,109,007 issued 28 Apr 92
Licensing Specialist: Arthur J. Cohn
A new method of treating ethyl alcohol intoxication through the use
of antagonists for the 2 adrenoceptor has been discovered.
Drugs based on these antagonists may have none of the potentially
harmful sedative effects of the tranquilizers currently used.
2 adrenoceptor agonists believed useful for this purpose
include: atipamexole, idazoxan, imiloxan, yohimbine, Wyeth WY26703,
Chinoin CH38083, Glaxo GR50360A, and Daiichi Seiyaku DG5128.
Rapid And Sensitive Test For Detecting Hepatitis A Virus
Robertson, B.H., Nainan, O.V., Brown, V.K., Margolis, H.S., Khanna, B.
(CDC)
Filed 31 Jan 92
Serial No. 07/828,444 (CIP of 07/469,143)
Licensing Specialist: Girish C. Barua
Diagnostic methods with improved sensitivity and specificity to
hepatitis A virus (HAV) are needed. This novel assay can be used to
test for general HAV infection as well as to differentiate between HAV
genotype I, which is thought to be the most common HAV, and HAV
genotype II, which differs genetically from HAV I (as well as HAV type
III) by about 15%. Free HAV is removed from stool, environmental
samples, and other materials by immunoselection of whole virus using
high titer anti-HAV antibodies coated onto a solid phase; viral RNA is
then denatured in the presence of primers that recognize all known HAV
genotypes and that bind to viral RNA for reverse transcription into
cDNA. PRC is used to amplify cDNA with Taq polymerase using either
labeled or unlabeled primers, depending on whether information on virus
type is desired. This novel method is faster and more specific than
currently available assays.
Production of Isolated Proteinaceous Materials Using Recombinant Avipox
Virus Vectors
Falkner, F.G., Dorner, F., Bodemer, W., Scheiflinger, F., Moss, B.
(NIAID)
Filed 11 May 92
Serial No. 07/882,768 (CIP of 07/734,741, CIP of 07/339,738)
Licensing Specialist: Girish C. Barua
This invention concerns the use of avipox viruses as vectors for
the expression of foreign DNA in animal tissue culture. The viruses are
constructed in the same convenient manner as recombinant vaccinia
viruses, by recombination of a recombinant plasmid with wild type
avipox virus. They have an advantage over vaccinia viruses in not being
pathogenic for humans or mammals. The recombinant avipox viruses can,
however, infect mammalian cell cultures as well as avian cell cultures.
Eukaryotic Expression Vector System
Giri, C.P., Ogawa, H., Harris, C.C. (NCI)
Filed 22 Mar 93
Serial No. 08/034,652
Licensing Specialist: Carl C. Floyd, Ph.D.
The method presented here allows for the enrichment of full length
cDNAs of genes selected by their phenotypes. This is achieved by
providing a vector system capable of synthesizing sense and antisense
RNAs in vitro to generate RNA probes for use in an RNA:RNA
hybridization based subtraction method. It also provides such an
RNA:RNA hybridization based subtraction method for enrichment of the
rare cDNs of interest. This will allow the selection of rare human
cDNAs, for example, where limited amounts of cells are available.
DNA Sequence Which Acts as a Chromatin Insulator Element To Protect
Expressed Genes From Cis-Acting Regulatory Sequences
Chung, H.J. Felsenfeld, G. (NIDDK)
Filed 7 Apr 93
Serial No. 08/045,266
Licensing Specialist: Carl C. Floyd, Ph.D.
Novel method of insulating functional DNA domains introduced into
higher eukaryotic cells from the effects of the cell's cis-acting
regulatory elements. The invention represents the first pure insulator
to be demonstrated to function in human cells. The element promises to
be a useful tool in gene therapy, gene transfer techniques, and studies
involving gene regulation and other gene expression technologies.
Peptide Inhibitors of Protein Tyrosine Kinase--SH2 Interactions
Roller, P.P. Burke, T.R., Otaka, A., Nomizu, M. (NCI)
Filed 8 Jun 93
Serial No. 08/072,946
Licensing Specialist: Carl C. Floyd, Ph.D.
The invention relates to synthetic peptides which are inhibitors of
protein-protein interactions, specifically that interaction between a
protein having a src homology domain (SH2 domain) and a protein having
a phosphorylated tyrosine that is recognized by the SH2 domain. This
type of interaction occurs during cellular signal transduction
cascades. These cascades are central in the regulation of cellular
proliferation and therefore their control is of importance to
chemotherapeutic approaches to antitumor therapy.
Phosphonoalkyl Phenylalanine Compounds Suitably Protected for Use
In Peptide Synthesis
Burke, T.R., Smyth, M.S., Lim, B.B. (NCI)
Filed 8 Jun 93
Serial No. 08/073,088
Licensing Specialist: Carl C. Floyd, Ph.D.
Phosphono(difluromethyl)phenylalanine (F2Pmp) is a chemically and
enzymatically stable mimetic of phosphotyrosine. The molecule is
suitably protected for use in solid-phase peptide synthesis and could
be the reagent of choice for synthesis of peptides containing stable
phosphotyrosyl mimetics.
Three Highly Informative Microsatellite DNA Markers for Use In Human
Individualization
Merril, C.R., Polymeropoulos, M.H. (NIMH)
Filed 9 Jun 93
Serial No. 08/074,275
Licensing Specialist: Carl C. Floyd, Ph.D.
The present invention relates to genetic testing with polymorphic
DNA markers. The repeat sequences of the markers provide a rapid and
convenient high resolution process for distinguishing target nucleic
acid segments on the basis of nucleotide differences according to human
individualization wherein the nucleic acid segments differ in size. The
invention has several applications in the areas of forensic screening,
paternity and prenatal screening, as well as genetic mapping.
The First Immortalized Kaposi's Sarcoma Cell Line
Iskandar-Lunardi, Y.L., Gallo, R.C. (NCI)
Filed 20 Aug 93
Serial No. 08/110,175
Licensing Specialist: Carl C. Floyd, Ph.D.
Kaposi's Sarcoma (KS) is the most common malignancy in patients
with acquired immunodeficiency syndrome (AIDS) in the U.S. The present
invention makes available cell lines that provide a means for testing
anti-Kaposi's Sarcoma therapies in vitro, or a model animal system. The
invention allows therapies to be tested and dosages to be optimized
prior to testing in humans. The cell line also provides a means of
developing novel antitumor therapies and facilitates studies of factors
that influence the development and metastasis of malignancies.
The Cloning Of Perilipin Proteins
Londos, C., Greenberg, A.S., Kimmel, A.R., Egan, J.J. (NIDDK)
Filed 4 Oct 93
Serial No. 08/132,649
Licensing Specialist: Carl C. Floyd, Ph.D.
Perilipins are found at the surface of lipid storage droplets of
adipocytes. Little is known about the molecules on the surface of lipid
droplets that may be involved in lipid metabolism and trafficking. The
present invention provides isolated nucleic acid sequences which encode
a family of perilipin proteins as well as isolated, purified perilipin
proteins. These are useful as markers for differentiation of true
adipocyte cells from non-adipocyte cells which, as a result of
pathophysiological conditions, assume adipocyte characteristics.
Dated: April 11, 1994.
Donald P. Christoferson,
Acting Director, Office of Technology Transfer.
[FR Doc. 94-9932 Filed 4-22-94; 8:45 am]
BILLING CODE 4140-01-M